Seroatlas · Human Serome Atlas

HAS2

Hyaluronan synthase 2

Also known as: HYAS2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q92819
Gene
HAS2
Ensembl
ENSG00000170961
Chromosome
8
Canonical length
552 aa
Protein class
Disease related genes, Enzymes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters
Quaternary structure
Homodimer

OverviewNCBI Gene

Hyaluronan or hyaluronic acid (HA) is a high molecular weight unbranched polysaccharide synthesized by a wide variety of organisms from bacteria to mammals, and is a constituent of the extracellular matrix. It consists of alternating glucuronic acid and N-acetylglucosamine residues that are linked by beta-1-3 and beta-1-4 glycosidic bonds. HA is synthesized by membrane-bound synthase at the inner surface of the plasma membrane, and the chains are extruded through pore-like structures into the extracellular space. It serves a variety of functions, including space filling, lubrication of joints, and provision of a matrix through which cells can migrate. HA is actively produced during wound healing and tissue repair to provide a framework for ingrowth of blood vessels and fibroblasts. Changes in the serum concentration of HA are associated with inflammatory and degenerative arthropathies such as rheumatoid arthritis. In addition, the interaction of HA with the leukocyte receptor CD44 is important in tissue-specific homing by leukocytes, and overexpression of HA receptors has been correlated with tumor metastasis. HAS2 is a member of the newly identified vertebrate gene family encoding putative hyaluronan synthases, and its amino acid sequence shows significant homology to glycosaminoglycan synthetase (DG42) from Xenopus laevis, and human and murine hyaluronan synthase 1. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

552 residues, UniProt reviewed canonical sequence.

>Q92819|HAS2
     1  MHCERFLCIL RIIGTTLFGV SLLLGITAAY IVGYQFIQTD NYYFSFGLYG AFLASHLIIQ
    61  SLFAFLEHRK MKKSLETPIK LNKTVALCIA AYQEDPDYLR KCLQSVKRLT YPGIKVVMVI
   121  DGNSEDDLYM MDIFSEVMGR DKSATYIWKN NFHEKGPGET DESHKESSQH VTQLVLSNKS
   181  ICIMQKWGGK REVMYTAFRA LGRSVDYVQV CDSDTMLDPA SSVEMVKVLE EDPMVGGVGG
   241  DVQILNKYDS WISFLSSVRY WMAFNIERAC QSYFGCVQCI SGPLGMYRNS LLHEFVEDWY
   301  NQEFMGNQCS FGDDRHLTNR VLSLGYATKY TARSKCLTET PIEYLRWLNQ QTRWSKSYFR
   361  EWLYNAMWFH KHHLWMTYEA IITGFFPFFL IATVIQLFYR GKIWNILLFL LTVQLVGLIK
   421  SSFASCLRGN IVMVFMSLYS VLYMSSLLPA KMFAIATINK AGWGTSGRKT IVVNFIGLIP
   481  VSVWFTILLG GVIFTIYKES KRPFSESKQT VLIVGTLLYA CYWVMLLTLY VVLINKCGRR
   541  KKGQQYDMVL DV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against HAS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
7
Mean surface accessibility (rSASA)
0.24
Highest tissue expression
21 nTPM

Expression across tissuesHPA

Tissue

  • adipose tissue: 21 nTPM
  • urinary bladder: 19 nTPM
  • appendix: 8.5 nTPM
  • gallbladder: 7.2 nTPM
  • rectum: 5.3 nTPM
  • breast: 4.9 nTPM

Single-cell type

  • fibroblasts: 122 nCPM
  • early spermatids: 111 nCPM
  • fibro-adipogenic progenitors: 56 nCPM
  • oligodendrocyte progenitor cells: 44 nCPM
  • medullary thymic epithelial cells: 41 nCPM
  • decidual stromal cells: 37 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • midbrain: 4.3 nTPM
  • medulla oblongata: 3.5 nTPM
  • hypothalamus: 3.2 nTPM
  • pons: 2.4 nTPM
  • thalamus: 2.4 nTPM
  • spinal cord: 2.3 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.28
gnomAD pLI
0.99
gnomAD missense Z
2.79
DepMap mean gene effect
-0.05
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads HAS2 as an antibody target. Whether an autoantibody or antibody against HAS2 could matter depends on whether native HAS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

HAS2 is annotated at the cell surface, where native HAS2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label HAS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/HAS2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...